Home » Stocks » XCUR

Exicure, Inc. (XCUR)

Stock Price: $1.55 USD -0.13 (-7.74%)
Updated May 13, 2021 3:09 PM EDT - Market open
Market Cap 153.99M
Revenue (ttm) 16.61M
Net Income (ttm) -24.67M
Shares Out 87.20M
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $1.55
Previous Close $1.68
Change ($) -0.13
Change (%) -7.74%
Day's Open 1.66
Day's Range 1.47 - 1.73
Day's Volume 595,045
52-Week Range 1.38 - 3.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago - Zacks Investment Research

Exicure, Inc. (XCUR) delivered earnings and revenue surprises of -50.00% and -95.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spherical Nucleic Acid technology shows promising results in phase 0 trial in patients with glioblastoma at Northwestern University.

2 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure reported fourth quarter and full year financial results for the year ended December 31, 2020 and provided an update on corporate progress.

2 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of Elizabeth (Betsy) Garofalo, M.D. and Mr. Andrew Sassine to its Board of Directors.

2 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--The U.S. FDA has granted Exicure Orphan Drug Designation for its clinical product candidate, cavrotolimod.

2 months ago - Business Wire

Exicure, Inc. (XCUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that CEO David Giljohann will present at the 2021 H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021.

2 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced participation in 10th Annual SVB Leerink Global Healthcare Conference.

3 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure CEO, David Giljohann, will present at the 2021 BIO CEO & Investor Digital Conference, February 16-18, 2021.

3 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that the U.S. FDA has granted Fast Track designations for cavrotolimod (AST-008) for two development programs.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced the appointment of James Sulat to its Board of Directors.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that David Giljohann, CEO, will present at the HC Wainwright Virtual BIOCONNECT Conference, January 11-14, 2021.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced that it will host a virtual R&D Day on January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure's neuroscience pipeline.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that the U.S. Patent and Trademark Office has issued two new patents and allowed U.S. patent application 14/907,430.

4 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. will participate in the 2020 Guggenheim Healthcare Talks | Idea Forum | Neuro/Immunology Day and the Virtual Fall Investor Summit.

5 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure, Inc. today reported third quarter 2020 financial results and corporate progress.

6 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure presents positive clinical data with cavrotolimod at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

6 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced an upcoming poster presentation for cavrotolimod (AST-008), at the 35th Anniversary Annual Meeting of SITC.

6 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure announced a presentation at the Chardan Virtual 4th Annual Genetic Medicines Conference on Monday, October 5, 2020.

7 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced it has entered into a $25.0 million senior secured term loan with MidCap Financial Trust and Silicon Valley Bank.

7 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual Key Opinion Leader (KOL) event to present preliminary Phase 1b efficacy and safety data.

7 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced presentations at two upcoming conferences during the month of September.

8 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure will host a virtual KOL meeting on September 16th, 2020 to discuss the preliminary Phase 1b efficacy and safety data for cavrotolimod.

8 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today reported financial results for the quarter and six months ended June 30, 2020 and provided an update on corporate progress.

9 months ago - Business Wire

CHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exicure today announced that David Giljohann, CEO, will present a Fireside Chat at the BTIG Virtual Biotechnology Conference 2020.

9 months ago - Business Wire

Shares of Exicure Inc. XCUR, +3.46% gained 6% in premarket trading after it said that it will start enrolling patients in a Phase 2 trial for the biotech's experimental immuno-oncology drug.

1 year ago - Market Watch

Shares of the thinly traded micro-cap Exicure Inc (NASDAQ: XCUR) were advancing strongly Thursday in the wake of a collaboration agreement announced by the company with Allergan plc (NYSE: AGN).

Other stocks mentioned: AGN
1 year ago - Benzinga

Shares of Exicure XCUR, -4.65% are up 26% in premarket trading on the news that the biotechnology company entered into an agreement with Allergan AGN, -0.20% to develop treatments for hair loss disorders.

1 year ago - Market Watch

About XCUR

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNA?based therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
David Giljohann
Employees
63
Stock Exchange
NASDAQ
Ticker Symbol
XCUR
Full Company Profile

Financial Performance

In 2020, Exicure's revenue was $16.61 million, an increase of 1,181.87% compared to the previous year's $1.30 million. Losses were -$24.67 million, -6.22% less than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Exicure stock is "Strong Buy." The 12-month stock price forecast is 11.00, which is an increase of 609.68% from the latest price.

Price Target
$11.00
(609.68% upside)
Analyst Consensus: Strong Buy